Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have participated in a randomized qualifying study of CP-690,550 for the treatment of rheumatoid arthritis~Vaccine sub-study visit~* Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by \>80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.~Exclusion Criteria:~* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe~Vaccine sub-study visit~1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study~2. Received any vaccine within 1 month prior to randomization in this study~3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label Active Treatment Enrolled from Phase 2 (Type: EXPERIMENTAL): Patients enrolling from Phase 2 studies
- Open-Label Active Treatment Enrolled from Phase 3 (Type: EXPERIMENTAL): Patients enrolling from Phase 3 studies

Based on this trial design, predict the completion outcome and termination type (if applicable).